MiNK Therapeutics' stock rises after HC Wainwright upgrade due to its promising allogeneic invariant natural killer T cell therapies for cancer and immune-mediated diseases.

MiNK Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing allogeneic invariant natural killer T cell therapies for cancer and immune-mediated diseases. Its lead product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. The company also has engineered programs, including MiNK-413 and MiNK-215, targeting B cell maturation antigen and tumor stromal targeting FAP-CAR-iNKT, respectively.

MiNK Therapeutics, Inc. (INKT) reported significant clinical and financial milestones in its second quarter (Q2) 2025 earnings call, demonstrating the company's progress in developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases.

Clinical Highlights

The company achieved a notable clinical milestone with the publication of a landmark case study in Nature's Oncogene, detailing a durable complete remission in a 49-year-old man with metastatic testicular cancer following a single infusion of agenT-797 (allo-INKTs) in combination with checkpoint blockade. This publication further solidified MiNK's position as a leader in iNKT cell therapy [1].

MiNK also reported a greater than 40% tumor shrinkage in a refractory gastric cancer patient, prompting an ongoing Phase II trial at Memorial Sloan Kettering Cancer Center. The company is also advancing programs in graft-versus-host disease (GvHD) and acute respiratory distress syndrome (ARDS), with the GvHD Phase I trial expected to begin enrollment this year and a randomized Phase II/III ARDS study anticipated soon, both with substantial external funding [1].

Financial Performance

MiNK reported a net loss for the second quarter 2025 of $4.2 million or $1.06 per share, compared to $2.7 million or $0.73 per share for the same period in 2024. For the first six months of 2025, net loss was $7 million or $1.76 per share, compared to $6.5 million or $1.82 per share for the same period last year. The operating cash burn for Q2 was reduced by over 30% year-over-year, reflecting the company's operational efficiencies. Additionally, MiNK raised an additional $13 million through equity sales post-quarter, further strengthening its cash position and extending its runway through the middle of next year [1].

Funding and Partnerships

The company received significant non-dilutive funding, including a Department of Defense STTR Grant to advance iNKTs in GvHD and a new clinical grant to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in the second half of 2025. These grants, coupled with MiNK's cash position, will enable substantial clinical program advancements [2].

MiNK's management also highlighted ongoing strategic partnership discussions, with increased market capitalization following the Oncogene publication, signaling growing investor confidence in iNKT therapies.

Outlook

Jennifer S. Buell, President and CEO, projected several catalysts ahead, including top line data from the Phase II gastric cancer trial by the end of 2025, the initiation of the GvHD Phase I trial, and further advancement of the MiNK-215 engineered iNKT program. She stated, "With a lean cost structure, a strong balance sheet and multiple value-creating milestones ahead, MiNK is well positioned to advance multiple programs in parallel while preserving shareholder value" [1].

References

[1] https://seekingalpha.com/news/4485675-mink-therapeutics-outlines-multiple-late-stage-catalysts-and-targets-phase-ii-gastric-cancer
[2] https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-clinical-and-strategic-milestones-and